Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tradeshow Marketing Company Releases Corporate Update
Date : 11/17/2008 @ 8:30AM
Tradeshow Marketing Company Releases Corporate Update
SAMMAMISH, WA, Nov. 17 /PRNewswire-FirstCall/ -- Tradeshow Marketing Company, Ltd. (OTC:TSHO), a specialty product development and retail company with operations in North America, is pleased to provide the following corporate update from its President and CEO, Luniel de Beer.
"As many of you have noticed, our company has been undergoing some changes over the past few months. Since our last corporate update in July, you've seen some announcements of important appointments, a potential joint venture, and sadly, the closure of our two underperforming stores in Arizona. We've also all seen the major downturn in our country's economy and we've felt the squeeze of a country in recession.
Over the past couple of months, you've been inquiring about what the future holds for Tradeshow Marketing. Today, I tell you that I'm very excited about our future. So far, we've been able to drastically reduce our costs, and we've been fine-tuning our business plans for substantial growth in 2009.
Our immediate plans are to generate revenues through direct sales at trade shows and in-store kiosks, and we're ready to move forward with plans to revamp our e-commerce site and product selection. We're also excited about a product we've been testing at trade shows over the past couple of months and we're ready to launch our Holidays sales effort through trade shows, in-store kiosks, and ecommerce - more news on this shortly.
Our medium term plans are to focus on bringing a few exclusive products to television through infomercials and to build our brand and market strength through these efforts. We've been in negotiations for some exclusive and limited-rights products with plans to launch these in the US and Canada in 2009, which will allow us to capitalize on sales through our unique five-channel distribution model. We're also looking into generating advertising revenue through our internet channels.
Finally, our long term plan is still to build out our national retail chain, not only to further enhance our sales channels but also to create a national brand that will appeal to our customers and retail consumers wishing for accessibility and consistency in product selection, pricing, value, and customer service.
I would like to use this opportunity to thank each and every shareholder and investor for your patience to date, and I ask of you to help support our efforts as we grow our company organically and sustainably towards the success we've all been striving to achieve."
Safe Harbor Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company.
DATASOURCE: Tradeshow Marketing Company Ltd.
CONTACT: More information is available about Tradeshow Marketing Company
at http://www.tsmc.ca/; Media Contacts: Luniel de Beer, President & CEO, Tradeshow
Marketing Company, , (425) 256-2283
BANI- 1.64 125k-vol, Take a look at the chart Don!! Should see 3 or 4 bucks easy IMO. http://stockcharts.com/h-sc/ui?s=bani Banneker, Inc, is a manufacturer and distributor of quality watches and fine jewelry based on the legend of Benjamin Banneker. Benjamin Banneker was an African-American mathematician and scientist who carved America's first functional clock. Esteem Enterprises, a wholly owned subsidiary of Banneker, Inc, teamed with Jostens, Inc. and created the first ever urban line of graduation jewelry and class rings.
Partners
Jostens, Inc.
Minneapolis-based Jostens, founded in 1897, is a leading provider of products, programs and services that help people celebrate important moments, recognize achievements and build affiliations. The company does over $850 Million in revenues per year. The company's products include yearbooks, class rings, graduation products and products for athletic champions and their fans
http://www.jostens.com/
http://www.hoovers.com/jostens/--ID__10828--/free-co-factsheet.xhtml
Jostens Company Description
Are you sure you want to remember high school? If so, look to Jostens, the leading US producer of yearbooks and class rings. Class rings are sold on school campuses and through bookstores, retail jewelers, and the Web, while Jostens' sports rings commemorate professional sports champions (it has made 27 Super Bowl rings). Other graduation products include diplomas, announcements, caps, and gowns. The company sold its school photography business in mid-2006. Founded in 1897, Jostens was sold to a unit of CSFB in 2003. The next year Jostens was recapitalized and became part of a newly created publishing and marketing services company, Visant, co-owned by an affiliate of CSFB and Kohlberg Kravis Roberts.
Getting closer to 10,500. The bounce today confirms in my mind that the market is starting to find a bottom. Looks like retailers are starting to take the lead.
Looks like the Dow is going to close in the 10k area. I think it could go to the 10,500 area and hold there for a while until there is leadership in the market. Money has been made on oil and I don't see $100 oil anytime in the near future. Natural gas could go back to the $10 range this winter if it is cold but I wouldn't bet on it. Metals is a wild card, maybe too risky from here. I think retailers will be leading for the rest of the year with some tech stocks to boot.
hey dons...que vola barbaro....im researching some stocks..ill share the good ones for what its worth....im still in ARET. waiting for that news.....
BIRD FLU NEWS
Indonesian nurse with bird flu-like symptoms hospitalized
UPDATED: 11:28, June 03, 2006
A 25-year old nurse identified by her initials as "Ci" is currently being treated at the Hasan Sadikin Hospital for bird flu-like symptoms in Bandung, capital of West Java province, Indonesia.
Ci was admitted to the hospital which has been treating a number of bird flu patients on Thursday evening, Antara news agency reported on Friday.
"When she arrived at this hospital last night, her body temperature was very high, namely 39.6 Celsius degrees but now it has decreased to 37 Celsius degrees," Hadi Jusuf, head of the bird flu medical treatment unit of the hospital, was quoted as saying Friday.
The hospital was planning to send the patient's blood sample to the laboratory of the Health Development and Research Body in Jakarta.
"We could not confirm whether she is positive of having been infected by avian influenza virus or not, although she had earlier have contacts with siblings, 18-year old Ad and 10-year old Ai, who died of bird flu virus recently," he said.
The ailing nurse has never had contact with poultry, but she had treated the sibling when being treated at Ujungberung Hospital, where Ci works as a nurse.
If she is confirmed of being infected by bird flu virus, it would be the first case of human-to-human transmission of the virus, he said.
Meanwhile, the UN World Health Organization (WHO) recently announced that international health investigators were finding no evidence that efficient transmission of the highly pathogenic avian influenza virus has emerged from a family cluster of cases in Indonesia's North Sumatra.
The H5N1 virus has caused 127 deaths in 224 cases worldwide since it was detected in humans in late 2003. In all but a handful of cases, humans have become infected through direct contact with ailing birds, their feces or blood.
Indonesia has detected 49 cases of H5N1, 31 of those appearing since January, and ending in 37 fatalities.
I'm still around just waiting for the market to bottom, which like I said could be back in the DOW 10k range...it's getting closer
Dow 11,098.35 26.98 (0.24%)
BIRD FLU NEWS
How Did Seven Family Members Get Infected With Bird Flu?
19 May 2006
We still don't know how seven members of the same family in Indonesia became infected with the H5N1 bird flu virus strain. Six of them have died. It is vital to know whether some of them infected each other. If they did, this would mean that the virus might be changing.
The World Health Organization says that it is highly unlikely that H5N1 has mutated in this case. If it had, WHO believes more people from outside the family would have become infected.
The problem is that many days have passed and no one has managed to find any other source. If they had become infected by sick chickens or ducks, surely they would have been traced by now.
Henry Niman, Ph.D., President of Recombinomics, is calling for the release of the human H5N1 bird flu sequences from the dead family members which are held in the WHO database. He said the bimodal distribution of infection, starting with the index case who became ill on April 27, to family members in early May, indicates the possibility of human-to-human transmission. It is vital to know whether/how the H5N1 genome has changed.
Scientists fear that when the H5N1 bird flu virus strain mutates, it will gain the ability to transmit from human to human. At the moment it cannot do that easily. If it does manage to mutate in this way, we could be facing a serious flu pandemic. Nobody knows what the mutated virus will be like - it could be extremely lethal or relatively harmless.
Nowhere in the world so far, except in this case in Indonesia, have so many people of the same family become infected within a few days of each other.
Indonesia's neighbours are increasingly nervous at its inability to stop the bird flu spread. New cases of sick chickens have been reported in the eastern Papua province - which has alarmed Australia.
Over 200 million chickens live in people's backyards in Indonesia. This makes it especially hard to contain the bird flu spread and to really know how many sick chickens there are.
Indonesian authorities seem unable to cope with the task of implementing measures to control avian flu at the district level. Different regions of the country are doing what they can with very little supervision from central authorities.
WHO has urged Indonesian authorities to do more to raise public awareness.
Thailand and Vietnam have been praised for their effective efforts in containing the spread of avian influenza.
BIRD FLU NEWS:
Rate of bird flu deaths in Indonesia causes alarm
http://www.abc.net.au/am/content/2006/s1642346.htmSTORY
AM - Friday, 19 May , 2006 08:12:00
Reporter: Geoff Thompson
TONY EASTLEY: The World Health Organisation says human-to-human transmission of the bird-flu virus cannot be ruled out as the cause of an alarming cluster of human infections in Northern Sumatra.
20 people have now died of the virus in Indonesia this year.
While the Northern Sumatra cluster has not spread widely, bird flu experts are concerned by Indonesia's inability to contain it.
Geoff Thompson reports from Jakarta.
GEOFF THOMPSON: Five more bird flu deaths have been confirmed in Indonesia this week, meaning that more people are now dying of the virus in Indonesia than in any other country.
That stark truth prompted Indonesia's President, Susilo Bambang Yudhoyono, to appeal for international help yesterday, while addressing the UN's Food and Agriculture Organisation.
SUSILO BAMBANG YUDHOYNO: The stakes so high that the FAO must never cease reminding the international community to give full financial and technical support in the fight against avian influenza.
GEOFF THOMPSON: Particularly worrying is a cluster of seven mostly fatal human infections in Northern Sumatra.
Sari Setiogi is spokeswoman for the World Health Organisation in Indonesia.
SARI SETIOGI: It is true that what happened in North Sumatra is the largest cluster that we've ever had, both in Indonesia and globally. And every time there is a cluster case it will raise the suspicions that human-to-human transmission might have occurred.
However, as of yet, our investigation shows that there's no evidence of further spread of the virus beyond this family cluster.
GEOFF THOMPSON: A total of 31 people have now died from avian influenza in Indonesia. But what is frustrating health professionals is the fact that not a single source of infection has ever been confirmed for any of those deaths.
Yesterday, Indonesia's Agriculture Minister Anton Apriyantono reported that 10 pigs had tested positive for bird flu in the same village as the human cluster. Pigs are regarded as mixing vessels in which human and bird flu viruses can swap genes and potentially produce more easily transmissible mutations.
The pig test results need to be confirmed internationally. But an Australian bird flu expert who has worked in Indonesia for eight years, has an even greater concern.
Dr Andrew Jeremijenko says that some of the cluster patients were released back into the community before returning to hospital to die.
ANDREW JEREMIJENKO: This had been a test to see whether Indonesia could control a pandemic virus. Basically they just failed the test.
We now know it was a large cluster, there was possible human-to-human transmission and we have pigs testing positive.
Discharging a patient and then allowing him to come back a few days later when he was very, very sick and died is dangerous.
GEOFF THOMPSON: Bird flu has now also been confirmed in Papua, less than two hundred kilometres from the Australian mainland.
In Jakarta, this is Geoff Thompson for AM.
NVAX
NEXT GENERATION VACCINE PRODUCTION
Conference Call Earnings and guidance:
http://biz.yahoo.com/cc/2/68932.html
You can listen to "the minute marker" to review areas of interest!
NOVAVAX CONFERENCE SLIDE PRESENTATION:
http://library.corporate-ir.net/library/71/711/71178/items/198048/051506Q106.pdf
NVAX has many new products in their pipeline, as well as, the next generation vaccine production.
NVAX
bellwetherreport.com: BellwetherReport.com Issues Morning Alert for Novavax Inc.
May 19, 2006 (M2 PRESSWIRE via COMTEX) -- The Bellwether Report Takes Notice of Novavax Inc. (Nasdaq:NVAX) Novavax has a thing for women and their health. The company focuses primarily on prescription pharmaceuticals for women. It sells such products as pre-natal vitamins, oral contraceptives, and hormone replacement therapies. The company's topical creams include ESTRASORB and ANDROSORB, which deliver estrogen and testosterone through the skin. Novavax is also developing vaccines for the flu, HIV/AIDS, melanoma, and E-selectin tolerogen (secondary stroke prevention). In addition, the company is developing a vaccine for hepatitis E in collaboration with GlaxoSmithKline.
Shares were up 3% following the announcement that the Company will develop a novel medicine for women.
Novavax, Inc. today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).
Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II
clinical development.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory
milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from.....
I don't have the hang of this system and forget I have to )re-type) the stock name!
NVAX 4.49 + .06 High 4.64
Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
via COMTEX
May 19, 2006
Esprit Receives North American Marketing Rights
MALVERN, Pa., May 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Novavax, Inc. (Nasdaq: NVAX), today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).
Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II clinical development.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from this new agreement will be similar in scope to our prior license agreement with Esprit executed last year. Esprit will be responsible for all development costs and will lead clinical programs. Novavax will be responsible for manufacturing the product in its existing state-of-the-art facility located in Philadelphia.
"We are delighted with our second new partnership with Esprit and believe that we have the opportunity to develop and commercialize a best-in-class product for women with HSDD," said Ray Hage, Senior Vice President and Chief Operating Officer of Novavax. "John Spitznagel and his team at Esprit have a remarkable track record of launching successful new products and this product will be a strong addition to their portfolio."
Novavax first collaborated in a business relationship with Esprit late last year when Esprit licensed Novavax's estrogen therapy lotion, ESTRASORB(R), in North America.
"We are very excited about adding this key development program to our product pipeline," said John T. Spitznagel, Esprit's Chairman and Chief Executive Officer. "Novavax's unique technology delivers testosterone through the skin in a therapeutically effective and easy-to-use lotion. This product will be very appealing to women who suffer from this condition."
Novavax President and Chief Executive Dr. Rahul Singhvi, President said the agreement "further substantiates Novavax's capabilities in product development and validates the company's novel delivery system as an important technology." The U.S. Food and Drug Administration approved ESTRASORB(R), Novavax's first lotion therapy, in 2003.
"We are confident that our novel technology will continue to enable us to develop products that have the potential to improve patient health and quality of life as well as provide unique opportunities for companies like Esprit," Dr. Singhvi said.
About Novavax, Inc.
Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.
4.49 + .06 High 4.64
Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
via COMTEX
May 19, 2006
Esprit Receives North American Marketing Rights
MALVERN, Pa., May 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Novavax, Inc. (Nasdaq: NVAX), today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).
Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II clinical development.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from this new agreement will be similar in scope to our prior license agreement with Esprit executed last year. Esprit will be responsible for all development costs and will lead clinical programs. Novavax will be responsible for manufacturing the product in its existing state-of-the-art facility located in Philadelphia.
"We are delighted with our second new partnership with Esprit and believe that we have the opportunity to develop and commercialize a best-in-class product for women with HSDD," said Ray Hage, Senior Vice President and Chief Operating Officer of Novavax. "John Spitznagel and his team at Esprit have a remarkable track record of launching successful new products and this product will be a strong addition to their portfolio."
Novavax first collaborated in a business relationship with Esprit late last year when Esprit licensed Novavax's estrogen therapy lotion, ESTRASORB(R), in North America.
"We are very excited about adding this key development program to our product pipeline," said John T. Spitznagel, Esprit's Chairman and Chief Executive Officer. "Novavax's unique technology delivers testosterone through the skin in a therapeutically effective and easy-to-use lotion. This product will be very appealing to women who suffer from this condition."
Novavax President and Chief Executive Dr. Rahul Singhvi, President said the agreement "further substantiates Novavax's capabilities in product development and validates the company's novel delivery system as an important technology." The U.S. Food and Drug Administration approved ESTRASORB(R), Novavax's first lotion therapy, in 2003.
"We are confident that our novel technology will continue to enable us to develop products that have the potential to improve patient health and quality of life as well as provide unique opportunities for companies like Esprit," Dr. Singhvi said.
About Novavax, Inc.
Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.
Do we have any TA experts here?
http://stockcharts.com/h-sc/ui?s=NVAX&p=D&yr=1&mn=0&dy=0&id=p87328075951&a=7...
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
NVAX- loss gets better (.11) vs (.22) or (5.5) vs (8.9 million)
Looking better, Barb, even beat the steet estimates.
Bush sends 6,000 troops to Mexico border, about time.
"We do not yet have full control of the border, and I am determined to change that."
How many years have the experts talked about how bad our borders are now? Anyone could come in here through our borders to cause another 9-11 or worse.
Oscar, I see IPRE is still rising. If that thing goes up to .20 I will scream for not getting in.
I am so tired of how the mms play games with these stocks. Shaking the tree is one thing but what they do sometimes is pathetic,
trying to free up some cash...but im chooking today...
10q is filed... it's now a profitable gold company
http://www.sec.gov/cgi-bin/browse-edgar?company=Goldspring&CIK=&filenum=&State=&SIC=....
good call, they are about to release their 2006 finacials and its positive....
Oscar, take a look at GSPG, I just bought some a few minutes ago.
Good Morning gem players.....on the menu this morning we have:
IPRE
WGFL
IDCN
ARETE
Good luck to all, and may we all be grEEEEEEEEEEEEEEEn.
Inflation data may give stocks whiplash
Sun May 14, 2006 11:25am ET
http://today.reuters.com/news/newsarticle.aspx?type=businessNews&storyid=2006-05-14T152508Z_01_N...
By Caroline Valetkevitch
NEW YORK (Reuters) - Fasten your seat belts.
Stock investors could be in for a bumpy ride this week with widely watched inflation gauges likely to dictate the market's direction.
Worries about inflation and rising interest rates drove stocks down sharply late last week as gold hit a 26-year high and the Fed failed to give Wall Street a clear signal that it was ready to pause after nearly two years of raising rates.
Any signs of further price pressures on the economy in this week's data on consumer and producer prices could give investors more reason to sell.
"Investors are just going to be very sensitive to any type of overheating of the economy," said Owen Fitzpatrick, head of the U.S. equity group at Deutsche Bank Private Wealth Management in New York. "Any pickup on any inflation numbers will be magnified."
The U.S. Producer Price Index for April, expected at 8:30 a.m. (1230 GMT) on Tuesday, and the Consumer Price Index, scheduled for release at the same time on Wednesday, will be among this week's most important economic indicators.....
I would like to add my Happy Mother's Day to all the mothers out there as well. We sure could use more mothers out there who are like my dear mother. I was lucky enough to find a great woman to marry who turned out to be a great mom to our children as well.
Happy Mothers Day!
i shure do..look at the chart it still has plenty of room....another one to look at is IVFH...some contracts coming up this week....and arete, filled their 10k on friday, so the "e" will be coming of on tuesday and recieved a 25k deposit for a merger on a florida oil and gas company, that news should come out this week and it will rock!!!!!!!!!, Happy Mothers Day to all on gem dandy!!!!!!!!!!!!!
Oscar, how high did your portfolio go up this week, 300%? I had only modest gains myself. I am 60% cash as of a couple of weeks ago. I'm looking at stocks like crazy but I just can't seem to pull the trigger lately. I'm looking for some more FMNJ type of plays if any are out there. Do you think IPRE has the legs to keep running?
Barb, how are things going for you?
Been out all day working...
The DOW is acting like it wants to see the 10k mark again. We don't have anything going for the market except metals and who knows how long that may last. In my opinion, we will see a retrace and then a flat Summer, however, I hope we will see some buying in early Fall. High fuel costs and increasing interest rates are not a good combo for growth. I will start playing short term plays (flipping)for a while.
SOIGF 3.70 + 92 NEWS
Press Release Source: Strata Oil & Gas Inc.
Strata Oil & Gas Announces 2-for-1 Forward Stock Split, Oil Sands Project Update
Friday May 12, 4:00 pm ET
CALGARY, AB--(MARKET WIRE)--May 12, 2006 -- Strata Oil and Gas (OTC BB:SOIGF.OB - News) is pleased to announce that its Board of Directors has approved a two-for-one forward stock split of its common stock to shareholders of record at the close of business on May 10th, 2006. Trading will begin on a split-adjusted basis on May 12th, 2006.
"This forward stock split is intended to enhance trading liquidity and broaden share ownership," said Manny Dhinsa, president of the company.
Strata's Peace River Oil Sands project is located directly to the southwest of Blackrock's Seal project. Blackrock was just purchased by Shell Canada in a friendly $2.4 billion cash offer.
Production in the Peace River Oil Sands area, which was once thought to require expensive thermal operations, has now been shown to be viable using cold production technology (CHOPS). Strata's scientific team has analyzed data from 21 existing wells that have been drilled on Strata's leases and an additional 165 wells in the area surrounding them.
The company has announced that it has engaged a Calgary-based petroleum exploration firm to assist in the planning, permitting and execution of a core hole drilling program on its 100%-owned Peace River Oil Sands project. The company's scientific team has recommended initiation of aggressive exploration on its wholly owned 26,000 acre oil sands package. The Peace River oil sands region of Alberta is estimated to contain more than 188 billion barrels of oil [Alberta Department of Energy, Cold Heavy Oil Production With Sand In The Canadian Heavy Oil Industry, Dr. Maurice Dusseault, March 2002].
"We believe the upside on our Peace River leases is substantial. Strata is uniquely positioned to provide exceptional shareholder returns in a rising oil market, and to provide greater exposure to petroleum prices by maximizing our in-place resource per common share," says Mr. Dhinsa. Strata Oil & Gas is a junior petroleum exploration company, with its head office located in Calgary, Alberta.
Strata Oil & Gas is a trademark of Strata Oil & Gas Inc. This announcement contains forward-looking statements which involve risks and uncertainties that include, among others, limited operating history, risks related to petroleum exploration, limited access to operating capital, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. More information is included in Strata's filings with the Securities and Exchange Commission which may be accessed through the SEC's web site at http://www.sec.gov.
NVAX EARNINGS AND GUIDENCE MONDAY 5-15-06
The market is really in the dumpster today!
NVAX BUYING OPPORTUNITY
NOVAVAX INC (NasdaqNM:NVAX) Delayed quote data
Last Trade: 4.89
Trade Time: 12:53PM ET
Change: 0.20 (3.93%)
Prev Close: 5.09
Open: 5.09
Bid: 4.89 x 100
Ask: 4.89 x 400
1y Target Est: 6.50
Day's Range: 4.80 - 5.14
52wk Range: 0.70 - 8.39
Volume: 1,329,792
Avg Vol (3m): 6,400,820
Market Cap: 267.65M
P/E (ttm): N/A
EPS (ttm): -0.26
BUYING OPPORTUNITY!
NOVAVAX INC (NasdaqNM:NVAX) Delayed quote data
Last Trade: 4.89
Trade Time: 12:53PM ET
Change: 0.20 (3.93%)
Prev Close: 5.09
Open: 5.09
Bid: 4.89 x 100
Ask: 4.89 x 400
1y Target Est: 6.50
Day's Range: 4.80 - 5.14
52wk Range: 0.70 - 8.39
Volume: 1,329,792
Avg Vol (3m): 6,400,820
Market Cap: 267.65M
P/E (ttm): N/A
EPS (ttm): -0.26
3.30 + .52 1:07 pm
STRATA OIL & GAS INC (OTC BB:SOIGF.OB) Delayed quote data
Last Trade: 3.25
Trade Time: 12:51PM ET
Change: 0.47 (16.91%)
Prev Close: 2.78
Open: 3.25
Bid: 3.20 x 500
Ask: 3.25 x 500
1y Target Est: N/A
Day's Range: 2.50 - 4.40
52wk Range: N/A
Volume: 979,822
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A
WGFL, if it goes back down for the afternoon shake go in, its up 100% waite for the shake to take it to 30-40% im loading up....
IGII
Check it out!
IGII
http://www.otcbbcoverage.com/stocks/index.php?topic=30.0
IBSG International, Inc (IGII). is a holding company for three software subsidiaries: Intelligent Business Systems Group, Inc. (IBSG), a provider of turnkey digital service center software; Secure Blue, Inc., a Sarbanes-Oxley and security software solution provider and Intelligent Business Systems Development (IBSD), a software development, maintenance and data storage company.
Oscar, looks interesting, I'll keep an eye on it.
3.35 0.42 (14.33%)after hours
http://biz.yahoo.com/prnews/060511/to221.html?.v=27
SMTC Reports First Quarter Results
Thursday May 11, 4:45 pm ET
Reports 22% Growth in Quarter Over Quarter Revenue and Fourth Consecutive Quarter Of Profitability
TORONTO, May 11 /PRNewswire-FirstCall/ - SMTC Corporation (1) (Nasdaq: SMTX, TSE: SMX), a global electronics manufacturing services provider, today reported revenue of $59.9 million and net income of $1.0 million, or $0.06 per share, for the first quarter ended April 2, 2006, compared with revenue of $49.1 million and a net loss of $2.6 million, or $0.18 per share, for the quarter ended April 3, 2005. In the fourth quarter of 2005, the Company reported revenue of $58.1 million and net income of $1.4 million, or $0.10 per share. Net income in the fourth quarter of 2005 included an income tax recovery of $0.6 million, or $0.04 per share.
"Our first quarter performance demonstrates our continuing progress to attain satisfactory financial results", stated John Caldwell, President and Chief Executive Officer. "Growth in year over year quarterly revenue reflects the strength of our customers' businesses and the positive effect of new customer programs coming on stream. Our improved earnings result from stronger revenue and mix of business."
Gross profit for the first quarter of 2006 was $6.1 million, or 10.1% of revenue, compared with $4.9 million, or 8.4% of revenue, for the previous quarter and $2.0 million, or 4.1% of revenue, for the first quarter of 2005.
"Our first quarter results met our internal targets demonstrating our consistency in generating after tax profits and positive trending in revenue. As expected, we utilized approximately $6.0 million in cash to finance our growth and higher level of activity at the end of the quarter", stated Jane Todd, Senior Vice President and Chief Financial Officer.
"The Company affirms annual guidance provided last quarter indicating that 2006 will be a year of growth in both revenues and earnings", stated John Caldwell.
-------------------------------------------------------------------------
(1) Expressed in U.S. dollars
-------------------------------------------------------------------------
About the Company: SMTC Corporation is a global provider of advanced electronic manufacturing services. The Company's electronics manufacturing centers are located in; Boston, Massachusetts; San Jose, California; Toronto, Canada; and Chihuahua, Mexico, with a third party facility in Chang An, China. SMTC offers technology companies and electronics OEMs a full range of value-added services. SMTC supports the requirements of a growing, diversified OEM customer base primarily within the industrial, networking, communications and computing markets. SMTC is a public company incorporated in Delaware with its shares traded on the Nasdaq National Market System under the symbol SMTX and on The Toronto Stock Exchange under the symbol SMX. Visit SMTC's web site, www.smtc.com, for more information about the Company.
Note for Investors: The statements contained in this release that are not purely historical are forward-looking statements which involve risk and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. These statements may be identified by their use of forward-looking terminology such as "believes", "expect", "may", "should", "would", "will", "intends", "plans", "estimates", "anticipates" and similar words, and include, but are not limited to, statements regarding the expectations, intentions or strategies of SMTC Corporation. For these statements, we claim the protection of the safe harbor for forward-looking statements provisions contained in the Private Securities Litigation Reform Act of 1995. Risks and uncertainties that may cause future results to differ from forward-looking statements include the challenges of managing quickly expanding operations and integrating acquired companies, fluctuations in demand for customers' products and changes in customers' product sources, competition in the EMS industry, component shortages, and others discussed in the Company's most recent filings with securities regulators in the United States and Canada. The forward-looking statements contained in this release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ materially from those projected in the forward-looking statements.
+ + +
Company Financials To Follow
SMTC CORPORATION
Consolidated Unaudited Statements of Earnings (Loss)
(US dollars, in thousands, except share and per share data)
Three months ended
April 2, April 3,
2006 2005
------------------------------
Revenue $ 59,907 $ 49,110
Cost of sales 53,842 47,109
-------------- -------------
Gross profit 6,065 2,001
Selling, general and administrative
expenses, 3,912 3,402
Restructuring charges 0 104
-------------- -------------
Operating earnings (loss) 2,153 (1,505)
Interest 1,164 1,105
-------------- -------------
Earnings (loss) before income taxes 989 (2,610)
Income tax expense 38 33
-------------- -------------
-------------- -------------
Net earnings (loss) $ 951 $ (2,643)
-------------- -------------
-------------- -------------
Net earnings (loss) per share:
Basic $ 0.06 $ (0.18)
Diluted $ 0.06 $ (0.18)
-------------- -------------
-------------- -------------
Weighted average number of shares
outstanding:
Basic 14,641,333 14,641,333
Diluted 14,825,301 14,641,333
SMTC CORPORATION
Consolidated Balance Sheets
(US dollars, in thousands)
April 2, December 31,
2006 2005
-------------- -------------
(unaudited)
Accounts receivable $ 33,900 $ 26,899
Inventories 35,472 33,168
Prepaid expenses 2,133 1,698
-------------- -------------
71,505 61,765
Property, plant and equipment 24,817 25,651
Other assets 1,707 2,010
Deferred income taxes 619 619
-------------- -------------
$ 98,648 $ 90,045
-------------- -------------
-------------- -------------
Accounts payable $ 34,110 $ 30,939
Accrued liabilities 12,102 13,849
Income taxes payable 1,149 1,203
Current portion of long-term debt 5,466 4,633
Current portion of capital lease
obligations 1,116 1,542
-------------- -------------
53,943 52,166
Long-term debt 29,672 23,857
Capital lease obligations - -
Shareholders' equity 15,033 14,022
-------------- -------------
$ 98,648 $ 90,045
-------------- -------------
-------------- -------------
>>
--------------------------------------------------------------------------------
Source: SMTC Corporation
IVFH is pending disney contracts, check out the rsi its about to leave the 30 mark...could be a good play next week, might start tomorrow.......im out of messages for the day...goodnight all, see you in the morning
IDCN,FPPL,IPRE,CMBV, looking for a good friday with these boys....imo
IDCN- I'm out but it may continue on in the morning, I have to work tomorrow though, so taking no chances with a pinkie.
Thanks for the private reply, I'm sorry that I can't reply in private...still a freebie. Wow! sounds great. Do they need FDA approval for something like this?
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
111
|
Created
|
05/07/06
|
Type
|
Free
|
Moderator DonsHub | |||
Assistants odiaz28 BARBARO5606 |
Posts Today
|
0
|
Posts (Total)
|
111
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |